(Q24245886)

4

0 references

Rachel Churchill

7

0 references

Hugh McGuire

6

Hugh McGuire

0 references

Toshi A Furukawa

8

Toshi A Furukawa

0 references

Atsuo Nakagawa

3

Atsuo Nakagawa

0 references

Ichiro M Omori

1

Ichiro Omori

0 references

Norio Watanabe

2

Cochrane Database of Systematic Reviews

Norio Watanabe

0 references

publication date

19 July 2006

0 references

published in

0 references

cites work

Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006114

Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. British Association for Psychopharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006114

Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006114

Selective serotonin reuptake inhibitors versus tricyclic and heterocyclic antidepressants: comparison of drug adherence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006114

"Wish bias" in antidepressant drug trials?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006114

Effectiveness of antidepressants. Meta-analysis of dose-effect relationships in randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006114

Industry sponsorship and authorship of clinical trials over 20 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006114

Fluoxetine versus other types of pharmacotherapy for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006114

Are we going to increase the use of antidepressants up to that of benzodiazepines?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006114

Australian and New Zealand clinical practice guidelines for the treatment of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006114

Can we individualize the 'number needed to treat'? An empirical study of summary effect measures in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006114

Meta-analysis of effects and side effects of low dosage tricyclic antidepressants in depression: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006114

Imputing missing standard deviations in meta-analyses can provide accurate results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006114

The economic burden of depression in the US: societal and patient perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006114

Amitriptyline versus other types of pharmacotherapy for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006114

A rating scale for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006114

Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006114

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006114

Pharmaceutical industry sponsorship and research outcome and quality: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006114

Clinician's judgments of mental health.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006114

A New Depression Scale Designed to be Sensitive to Change

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006114

An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006114

A consumer's guide to subgroup analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006114

Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006114

Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006114

A systematic review of newer pharmacotherapies for depression in adults: evidence report summary

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006114

Imputing response rates from means and standard deviations in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006114

The World Health Organization quality of life assessment (WHOQOL): Development and general psychometric properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006114

Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: an analysis of the food and drug administration summary basis of approval reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006114

7 January 2021

Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006114

7 January 2021

Prevalence and outcomes of pharmaceutical industry-sponsored clinical trials involving clozapine, risperidone, or olanzapine.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006114

7 January 2021

Antidepressant drug consumption and public health indicators in Italy, 1955 to 2000.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006114

7 January 2021